 Omeros Corporation NASDAQ: OMER has revealed that the FDA needs additional time to review narsoplimab marketing application for hematopoietic stem cell transplant-associated thrombotic microangiopathy HSCT-TMA. The new target action date is October 17, compared to the earlier date of July 17. 